TEV-56286
Phase 2Small molecule
TevaTEV-56286 is one of 28 small molecule programs targeting Multiple System Atrophy. It is currently in Phase 2.
1
Indications
4
Total Trials
2
Active Trials
27
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
48 competitors in Multiple System Atrophy
#DrugCompanyPhaseTrials
1Northera
LundbeckApproved
Rifadin
SanofiApproved
Rilutek
AAzurity Pharmaceuticals
Approved
Sudafed
KKenvue Brands
Approved
Rifampicin
Boehringer IngelheimPhase 3
Byetta
AstraZenecaPhase 2
Rapamune
PPrism Pharmaceuticals
Phase 2
Lithobid
SSolvay Pharmaceuticals
Phase 2
Prozac
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 2
Lu AF95245
LundbeckPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Multiple System Atrophy2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TEV-56286. EMBL-EBI & Wellcome Sanger Institute.
- [4]